Omvoh (Mirikizumab) in Crohn's Disease: Three Years of Steroid-Free Remission and Significantly Reduced Hospitalization and Surgery Risks
Eli Lilly has released new long-term data for its drug Omvoh (mirikizumab) in moderately to severely active Crohn's disease. The results show that over 90% of patients who achieved steroid-free remission at one year maintained it through three years of continuous treatment. Additionally, the drug significantly reduced hospitalization and surgery rates in both Crohn's disease and ulcerative colitis patients, highlighting its potential to alter the long-term disease trajectory.